About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Melinta Therapeutics Announces IDWeek 2024 Presentations Focused on Melinta’s Portfolio of Commercial and Investigational Stage Products

Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced today, ten scientific presentations with data focused on Melinta’s portfolio of commercial and investigational stage products to be shared at Infectious Disease Week (IDWeek) 2024, Oct. 16-19, 2024, in Los Angeles, California.

IDWeek is the combined annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS), and the Society of Infectious Diseases Pharmacists (SIDP).

Details of the presentations are provided below. The complete program of titles and abstracts can be accessed on the IDWeek 2024 website at www.idweek.org.

Melinta and Alliance Partner Posters and Oral Presentations

Product and Presentation Type

Date/Time/Location

Title

Poster Number

Rezafungin

(poster)

Friday, Oct 18

12:15 PM – 1:30 PM

Activity of rezafungin against clinical isolates of uncommon species of candida spp.

1095

Rezafungin

(poster)

Friday, Oct 18

12:15 PM – 1:30 PM

Week one outcomes of rezafungin vs caspofungin treatment for candidemia and invasive candidiasis (CIC): pooled analysis of two randomized trials exploring optimal echinocandin duration

1034

Cefepime-taniborbactam

(poster)

Friday, Oct 18

12:15 PM – 1:30 PM

Cefepime-taniborbactam exhibits limited cross-resistance with ceftazidime-avibactam and ceftolozane-tazobactam against carbapenem-nonsusceptible enterobacterales and multidrug-resistant pseudomonas aeruginosa from the United States 2018-2022

1514

Cefepime-taniborbactam

(poster)

Friday, Oct 18

12:15 PM – 1:30 PM

Assessment of cefepime-taniborbactam (FEP-TAN) transmembrane clearance (CLTM) in an Ex vivo continuous renal replacement therapy (CRRT) model

1218

Cefepime-taniborbactam

(poster)

Friday, Oct 18

12:15 PM – 1:30 PM

Susceptibility of carbapenem-resistant enterobacterales (CRE) and carbapenem-resistant pseudomonas aeruginosa (CRPA) with and without carbapenemases to cefepime-taniborbactam and comparators: GEARS antimicrobial surveillance program, United States, 2018-2022

1521

Cefepime-taniborbactam

(poster)

Friday, Oct 18

12:15 PM – 1:30 PM

 

Cefepime pharmacodynamics against pseudomonas aeruginosa evaluated in a chemostat infection model: do generalized cephalosporin targets translate?

1241

Oritavancin

(poster)

Thursday, Oct 17

12:15 PM – 1:30 PM

Acute bacterial skin and skin structure infections: a comparison of outpatient one-hour infusion oritavancin and inpatient vancomycin use

735

Meropenem-vaborbactam

(poster)

Friday, Oct 18

12:15 PM – 1:30 PM

Unlocking potentials: the impact of meropenem, meropenem-vaborbactam, and ceftazidime-avibactam in combatting carbapenem-resistant enterobacter cloacae in epithelial lining fluid and serum

1258

Meropenem-vaborbactam

(poster)

Friday, Oct 18

12:15 PM – 1:30 PM

 

Patient characteristics and clinical outcomes associated with meropenem/vaborbactam treatment in carbapenem-resistant enterobacterales pneumonia

1499

Meropenem-vaborbactam

(oral presentation)

Thursday, Oct 17

3:15 PM – 4:30 PM

Room 403B

Population pharmacokinetics of meropenem-vaborbactam in acutely ill hospitalized patients with various degrees of renal dysfunction

Oral Presentation

About Melinta Therapeutics, LLC

Melinta Therapeutics is a biopharmaceutical company dedicated to providing innovative therapies to people impacted by acute and life-threatening illnesses. We focus our expanding portfolio on serving patients with an unmet need because that’s how we make the most meaningful impact. At Melinta, we’re visionaries dedicated to innovation while staying grounded in what matters most: patients. Our portfolio currently includes seven commercial-stage products: BAXDELA® (delafloxacin), KIMYRSA® (oritavancin), MINOCIN® (minocycline) for Injection, ORBACTIV® (oritavancin), REZZAYO® (rezafungin for injection), TOPROL-XL® (metoprolol succinate) and VABOMERE® (meropenem and vaborbactam). Melinta also licensed the U.S. commercial rights to the investigational agent cefepime-taniborbactam from Venatorx Pharmaceuticals in 2023. For more information about Melinta Therapeutics, our commitment to patients, and to learn about our portfolio of therapies, visit www.melinta.com.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.